Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform

DIANT Pharma's Antonio Costa, Ph.D., explains how DIANT Pharma’s tightly controlled, end-to-end adaptable production platform provides provides an ideal continuous manufacturing solution for achieving robust, scalable nucleic acid–LNP manufacturing.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: